Aaron Koenig
Company: Delix Therapeutics
Job title: Chief Medical Officer
Seminars:
Chair’s Closing Remarks 5:30 pm
day: Day One PM
Panel Discussion: Assessing the Pros & Cons of Muscarinic PAMs vs. Agonists for Side Effect Alleviation & Efficacy Across Symptom Domains 4:30 pm
What are the main advantages and disadvantages of preclinically developing and clinically investigating a muscarinic receptor agonist compared to a PAM, and how are the disadvantages currently being addressed? Evaluating differences in efficacy signals: are there specific indications where one approach might be more beneficial than the other? What are the differences in side effect…Read more
day: Day One PM
Roundtable Discussion: Navigating the Non-Static Nature & Complexity of Disease States to Develop More Precise Treatment Options for Bipolar & Substance Use Disorders 2:45 pm
More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas: How can we tailor therapies to address the different disease states of patients in high addiction phases vs detoxing vs maintaining sobriety? Is there a way to screen for different addiction states? How can we overcome…Read more
day: Day One Track B PM
Chair’s Closing Remarks & End of 8th Neuropsychiatric Drug Development Summit 4:30 pm
day: Day Two PM
Chair’s Opening Remarks 8:20 am
day: Day One AM